Search

Glaukos Corp

Fechado

SetorSaúde

223.52 2.05

Visão Geral

Variação de preço das ações

24h

Atual

Mín

218.07

Máximo

228.55

Indicadores-chave

By Trading Economics

Rendimento

20M

2M

Vendas

25M

211M

EPS

0.47

Margem de lucro

0.956

Funcionários

1,094

EBITDA

18M

12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+8.11% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.6B

14B

Abertura anterior

221.47

Fecho anterior

223.52

Glaukos Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de nov. de 2026, 21:02 UTC

Glaukos Corporation is seeing higher trading activity with unusually high volume, peaking earlier in the day while remaining above its 20-day moving average.

5 de nov. de 2026, 21:03 UTC

Glaukos Corporation shares fell sharply after a brief uptick, trading with unusually high volume while remaining above its 20-day moving average.

4 de nov. de 2026, 21:02 UTC

Glaukos Corporation shares are advancing, supported by strong trading volume, despite earlier pulling back from a session high. The health care equipment sector shows positive momentum.

3 de nov. de 2026, 20:51 UTC

Glaukos Corporation shares are declining, retracing from an earlier peak, despite remaining significantly above Monday's close amid unusually high trading volume.

2 de nov. de 2026, 20:56 UTC

News
Social Media

Glaukos Corporation will be added to the S&P MidCap 400 index, a development that may enhance its visibility among investors.

30 de out. de 2026, 19:42 UTC

Social Media

Glaukos Corporation shares fell amid a broader market downturn, with unusually high trading volume today.

29 de out. de 2026, 20:03 UTC

Social Media
News

Stock advances after return to profitability, $2 million net income.

28 de out. de 2026, 23:02 UTC

Social Media
News

Glaukos Corporation reported record Q3 net sales of $211 million and raised its 2026 sales guidance to between $775 million and $785 million.

27 de out. de 2026, 20:01 UTC

Glaukos Corporation shares are experiencing higher trading activity today, reaching a notable peak earlier in the session before pulling back slightly.

26 de out. de 2026, 23:46 UTC

Glaukos Corp shares are trading higher in after-market hours, remaining near the upper end of their one-month trading range.

22 de out. de 2026, 20:07 UTC

Glaukos Corp shares are declining, retracing from an early session peak to approach the day's low amid a slight overall market decline.

21 de out. de 2026, 20:07 UTC

Glaukos Corp shares advanced throughout Wednesday, peaking in the afternoon before a slight pullback, remaining above their 20-day moving average.

20 de out. de 2026, 20:01 UTC

Glaukos Corp shares are significantly higher, currently 7.32% above their 20-day moving average and near the upper end of their one-month range.

16 de out. de 2026, 19:36 UTC

Glaukos Corp shares fell sharply, marking a notable decline since Thursday's close and currently positioned around the midpoint of its one-month trading range.

15 de out. de 2026, 20:07 UTC

Glaukos Corp shares are declining, reversing an early spike to finish lower from Wednesday's close amid unusual volatility.

13 de out. de 2026, 20:07 UTC

Glaukos Corp shares are declining, following a volatile intraday pattern, closing lower from Monday's close despite briefly recovering earlier in the session.

9 de out. de 2026, 20:06 UTC

News
Event

Glaukos reports positive Phase 4 trial results for iDose TR therapy, showing a significant reduction in intraocular pressure alongside cataract surgery, confirming safety.

8 de out. de 2026, 22:55 UTC

Glaukos Corp shares declined in after-market hours, continuing a downward trend from Thursday's close and remaining below its 20-day moving average.

7 de out. de 2026, 20:00 UTC

Glaukos Corp is advancing significantly with unusually high trading volume, marking a departure from recent higher daily closes since Tuesday.

6 de out. de 2026, 20:07 UTC

Glaukos Corp shares are declining, trading below their 20-day moving average and near the lower end of their one-month range after earlier volatility.

1 de out. de 2026, 20:07 UTC

Glaukos Corp's shares are declining, positioned near the lower end of their one-month range, after a brief spike earlier in the session.

30 de set. de 2026, 20:07 UTC

Glaukos Corp shares are advancing, rebounding from an earlier pullback, amid a broader market trend of significant gains on Wednesday.

29 de set. de 2026, 23:55 UTC

Glaukos Corp is trading modestly higher in after-market hours, despite fluctuations during the session, and remains below its 20-day moving average.

28 de set. de 2026, 20:07 UTC

Glaukos Corp is gaining ground in today's trading session, reflecting upward momentum since Friday, despite earlier pulling back from a session high.

25 de set. de 2026, 20:07 UTC

Glaukos Corp shares fell sharply, closing just below Thursday's close and approximately 9.45% below their 20-day moving average.

23 de set. de 2026, 20:01 UTC

News

Glaukos Corporation launched a keratoconus awareness campaign with Stephen Curry, but shares fell sharply today, continuing a trend of three consecutive daily declines.

22 de set. de 2026, 23:01 UTC

Glaukos Corp is advancing in after-market trading, reflecting a directional move since Tuesday's close, though it remains 6.99% below its 20-day moving average.

21 de set. de 2026, 20:06 UTC

Glaukos Corp's shares are declining, remaining below their 20-day moving average and near the lower end of their one-month range despite an earlier session recovery.

18 de set. de 2026, 20:02 UTC

Glaukos Corp is advancing during market hours on Friday, continuing its upward trend since Thursday's close, despite lower trading compared to earlier sessions.

17 de set. de 2026, 19:36 UTC

Glaukos Corp shares fell sharply, currently at their lowest point of the day and significantly below the 20-day moving average.

Comparação entre Pares

Variação de preço

Glaukos Corp Previsão

Preço-alvo

By TipRanks

8.11% parte superior

Previsão para 12 meses

Média 237.818 USD  8.11%

Máximo 255 USD

Mínimo 210 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Glaukos Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

10

Comprar

1

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat